Addition of Tremelimumab to Durvalumab Regimen Induces Greater Survival Outcomes in PD-L1–Negative NSCLCAugust 8th 2022
The phase 3 POSEIDON trial showed superior overall survival in patients with PD-L1–negative metastatic non–small cell lung cancer who were given durvalumab and chemotherapy plus tremelimumab.
Gastrointestinal Cancers Exhibit Clear Benefit With Addition of Nivolumab to Chemotherapy, Regardless of TMB StatusApril 11th 2022
Results of CheckMate 649 trial show consistently improved outcomes across advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma when nivolumab is administered in combination with chemotherapy.
FDG and NaF PET/CT Predictive for Overall Survival in Genitourinary MalignanciesFebruary 19th 2022
At 2022 ASCO GU, early trial results show promise for fluorodeoxyglucose and sodium fluoride PET/CT prognostic ability to predict survival in patients with metastatic genitourinary malignancies treated with cabozantinib plus PD-1/CTLA-3 inhibition.